Greifswalder microbiome analysis colorectal cancer
Recruiting
- Conditions
- Malignant neoplasm of rectosigmoid junctionMalignant neoplasm of rectumMalignant neoplasm of colonC18C19C20
- Registration Number
- DRKS00025336
- Lead Sponsor
- niversitätsklinikum Greifswald
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 350
Inclusion Criteria
histologically confirmed CRC, or suspicion of CRC
- Age greater than or equal to 18 years
Exclusion Criteria
- Pregnancy/ nursing women
- Patients unable to give consent
- Secondary neoplasia < 5 years prior to study inclusion.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 16sRNA analysis of the microbiome (stool at initial diagnosis and postoperatively at primary surgery, or before neoadj. therapy and after completion, tumor tissue intraoperatively) in patients with CRC.
- Secondary Outcome Measures
Name Time Method Overall survival<br>Tumor-free survival<br>Changes of the microbiome under therapy by 16sRNA analysis
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link gut microbiome composition to colorectal cancer progression in DRKS00025336?
How does the GMA-CRC trial compare microbiome-based biomarkers to standard-of-care diagnostic tools for C18-C20 malignancies?
Which specific microbial taxa or metabolites in DRKS00025336 could serve as predictive biomarkers for CRC treatment response?
What adverse events are associated with microbiome dysbiosis in colorectal cancer patients enrolled in GMA-CRC?
How might findings from DRKS00025336 inform combination therapies targeting the microbiome and EGFR/VEGF pathways in CRC?